Filing Flows › Health Care › America Great Health (AAGH)
America Great Health (AAGH) earnings and revenue breakdown
Latest: Q3 FY26 · 10-Q filed Aug 6, 2026 · America Great Health (AAGH) Q3 FY26 earnings results →
Q3 FY26 Revenue down 53% year over year to $26K · 636¢ of every $1 of revenue lost · operating margin -282.2%
America Great Health made $26K in Q3 FY26 (-53% Y/Y): Anti Aging Immune Support $14K, Targeted System Support $10K, Herbal Insulin Support $2K. Operating margin -282.2%, net loss $166K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $26K in Q3 FY26, down 53% year over year and down 42% from the previous quarter. Anti Aging Immune Support was the largest line at 54% of revenue. Anti Aging Immune Support lost $36K year over year (down 72%), 120% of the total change.
Gross margin was 86.2%, down 2.5 points from Q3 FY25. Operating costs exceeded revenue by $74K, an operating margin of -282.2%. Operating expenses fell 29% while revenue fell 53%. The quarter ended with a net loss of $166K, after a profit of $1.1M the previous quarter. Minority interests bore $0K of it: to shareholders the quarter was a loss of $166K. Net interest and other expense of $92K was the main reason.
Operating cash flow was $2K. Non-cash charges added back $1K of depreciation. Working capital and other items added $167K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 FY26 | 10-Q | Aug 6, 2026 | $26K | -53% | -282.2% | −$166K | $2K |
| Q2 FY26 | 10-Q | Jun 22, 2026 | $45K | -50% | -440.7% | $1.1M | −$126K |
| Q1 FY26 | 10-Q | Jun 4, 2026 | $188K | +34% | -1.8% | −$85K | $44K |
| Q4 FY25 | 10-K | Apr 10, 2026 | $105K | +9% | -101.6% | −$222K | −$273K |
| Q3 FY25 | 10-Q | May 15, 2025 | $56K | -40% | -152.0% | −$158K | −$53K |
| Q2 FY25 | 10-Q | Apr 14, 2025 | $91K | -0.3% | -132.5% | −$194K | $89K |
| Q4 FY24 | 10-K | Feb 25, 2025 | $96K | +28% | -438.7% | −$592K | −$294K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About America Great Health
America Great Health, formerly Crown Marketing, is a Wyoming corporation (the “Company”). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.
In its own words, from its 10-K, filed Apr 10, 2026.
America Great Health against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -53% against the peers' median +7%. Operating margin: -282.2% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AAGH America Great Health | Q3 FY26 | $26K | -53% | -282.2% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: America Great Health 10-Q on SEC EDGAR · CIK 1098009 · Pharmaceutical Preparations
More on AAGH
History
Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q4 FY24 results